PURPOSE: The aim of this work was to demonstrate an immunostimulatory and adjuvant effect of new apyrogenic lipophilic derivatives of norAbuMDP and norAbuGMDP formulated in nanoliposomes. METHODS: Nanoliposomes and metallochelating nanoliposomes were prepared by lipid film hydration and extrusion methods. The structure of the liposomal formulation was studied by electron microscopy, AF microscopy, and dynamic light scattering. Sublethal and lethal γ-irradiation mice models were used to demonstrate stimulation of innate immune system. Recombinant Hsp90 antigen (Candida albicans) bound onto metallochelating nanoliposomes was used for immunisation of mice to demonstrate adjuvant activities of tested compounds. RESULTS: Safety and stimulation of innate and adaptive immunity were demonstrated on rabbits and mice. The liposomal formulation of norAbuMDP/GMDP was apyrogenic in rabbit test and lacking any side effect in vivo. Recovery of bone marrow after sublethal γ-irradiation as well as increased survival of mice after lethal irradiation was demonstrated. Enhancement of specific immune response was demonstrated for some derivatives incorporated in metallochelating nanoliposomes with recombinant Hsp90 protein antigen. CONCLUSIONS: Liposomal formulations of new lipophilic derivatives of norAbuMDP/GMDP proved themselves as promising adjuvants for recombinant vaccines as well as immunomodulators for stimulation of innate immunity and bone-marrow recovery after chemo/radio therapy of cancer.

Department of Pharmacology and Immunotherapy Veterinary Research Institute Hudcova 70 620 00 Brno Czech Republic

Zobrazit více v PubMed

Expert Opin Pharmacother. 2011 Feb;12 (2):285-92 PubMed

Vaccine. 1994 Feb;12(2):175-60 PubMed

Nat Immunol. 2006 Dec;7(12):1250-7 PubMed

J Control Release. 2012 Jun 10;160(2):374-81 PubMed

Immunity. 2007 Oct;27(4):549-59 PubMed

Crit Rev Ther Drug Carrier Syst. 1986;2(4):353-406 PubMed

Int J Immunopharmacol. 1997 Sep-Oct;19(9-10):611-7 PubMed

Nat Immunol. 2009 Dec;10(12):1267-74 PubMed

J Leukoc Biol. 2011 Feb;89(2):177-87 PubMed

Vaccine. 2006 Apr 12;24 Suppl 2:S2-90-1 PubMed

Nat Immunol. 2003 Jul;4(7):702-7 PubMed

Int J Immunopharmacol. 1989;11(6):653-61 PubMed

J Biol Chem. 2003 Oct 24;278(43):41702-8 PubMed

Genet Vaccines Ther. 2008 Sep 02;6:11 PubMed

Med Res Rev. 1984 Apr-Jun;4(2):111-52 PubMed

Adv Drug Deliv Rev. 2001 Aug 23;50(1-2):143-56 PubMed

Int Immunopharmacol. 2004 Aug;4(8):1099-106 PubMed

Infection. 1984 May-Jun;12(3):230-4 PubMed

Curr Med Chem. 2011;18(16):2438-51 PubMed

J Microbiol Biotechnol. 2009 Jul;19(7):727-33 PubMed

J Control Release. 2012 Jun 10;160(2):330-8 PubMed

Annu Rev Immunol. 1986;4:369-88 PubMed

Anal Biochem. 2011 Jan 1;408(1):95-104 PubMed

J Pharm Sci. 2010 May;99(5):2309-19 PubMed

Science. 1980 Apr 25;208(4442):415-6 PubMed

Folia Microbiol (Praha). 2007;52(3):297-312 PubMed

PLoS One. 2010 Oct 22;5(10):e15369 PubMed

Curr Biol. 2004 Nov 9;14 (21):1929-34 PubMed

Methods. 2006 Sep;40(1):39-52 PubMed

J Hepatol. 2010 Oct;53(4):693-701 PubMed

Scand J Immunol. 2011 Aug;74(2):126-34 PubMed

Anal Biochem. 1994 May 1;218(2):352-7 PubMed

Folia Microbiol (Praha). 2005;50(1):77-82 PubMed

Prescrire Int. 2011 Apr;20(115):89 PubMed

Parasitology. 2005 Nov;131(Pt 5):601-8 PubMed

Int Immunopharmacol. 2001 Jul;1(7):1249-59 PubMed

Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317-25 PubMed

J Endotoxin Res. 2006;12(2):69-85 PubMed

J Control Release. 2011 Apr 30;151(2):193-201 PubMed

The Position of His-Tag in Recombinant OspC and Application of Various Adjuvants Affects the Intensity and Quality of Specific Antibody Response after Immunization of Experimental Mice